Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings].
作者信息
Idle J R, Sloan T P, Smith R L, Wakile L A
出版信息
Br J Pharmacol. 1979 Jul;66(3):430P-431P.
Abstract
摘要
相似文献
1
Application of the phenotyped panel approach to the detection of polymorphism of drug oxidation in man [proceedings].表型分组方法在检测人体药物氧化多态性中的应用[会议论文集]
Br J Pharmacol. 1979 Jul;66(3):430P-431P.
2
Drug metabolism in uremia.尿毒症中的药物代谢。
Clin Nephrol. 1975;4(3):83-5.
3
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷：药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
4
Polymorphic drug oxidation in humans.人类的多态性药物氧化
Fed Proc. 1984 May 15;43(8):2298-302.
5
[Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].[氧化药物代谢的基因多态性。治疗和毒理学意义]
Internist (Berl). 1983 Mar;24(3):117-27.
6
Interindividual differences in rates of drug oxidation in man.人类药物氧化速率的个体差异。
Drug Metab Dispos. 1973 Jan-Feb;1(1):411-7.
7
Interindividual differences in drug oxidation: clinical importance.
Drug Metab Dispos. 1973 Jan-Feb;1(1):469-82.
8
[Alcohol and drugs].[酒精与毒品]
Tijdschr Gastroenterol. 1976;19(2):117-23.
9
Genetic factors in hepatic drug oxidation.肝脏药物氧化中的遗传因素。
Prog Liver Dis. 1976;5:246-58.
10
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.药物碳中心氧化的多态性及其临床意义。
Drug Metab Rev. 1979;9(2):301-17. doi: 10.3109/03602537908993896.
引用本文的文献
1
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.土耳其人群中细胞色素P450 CYP2C9变体的频率及其与苯妥英的功能相关性。
Br J Clin Pharmacol. 1999 Sep;48(3):409-15. doi: 10.1046/j.1365-2125.1999.00012.x.
2
Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.人肝脏微粒体组分中异喹胍4-羟化酶活性的测定与表征
Br J Clin Pharmacol. 1982 May;13(5):637-45. doi: 10.1111/j.1365-2125.1982.tb01430.x.
3
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷：药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
4
Ethnic differences in drug metabolism.药物代谢中的种族差异。
Clin Pharmacokinet. 1982 Sep-Oct;7(5):373-400. doi: 10.2165/00003088-198207050-00001.
5
Sulphaphenazole and drug oxidation in man.磺胺苯吡唑与人的药物氧化作用
Br J Clin Pharmacol. 1983 Oct;16(4):460-1. doi: 10.1111/j.1365-2125.1983.tb02199.x.
6
Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.人体中S-羧甲基-L-半胱氨酸多峰分布硫氧化的遗传因素
Br J Clin Pharmacol. 1984 Oct;18(4):507-21. doi: 10.1111/j.1365-2125.1984.tb02498.x.
7
Assessment of methods to identify sources of interindividual pharmacokinetic variations.个体间药代动力学差异来源识别方法的评估
Clin Pharmacokinet. 1983 Sep-Oct;8(5):378-409. doi: 10.2165/00003088-198308050-00002.
8
Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.
Eur J Clin Pharmacol. 1983;24(6):797-9. doi: 10.1007/BF00607090.
9
Assessment of the drug metabolism capacity of the liver.肝脏药物代谢能力的评估。
Br J Clin Pharmacol. 1982 Nov;14(5):631-51. doi: 10.1111/j.1365-2125.1982.tb04950.x.
10
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
本文引用的文献
1
Polymorphism of carbon oxidation of drugs and clinical implications.药物碳氧化的多态性及其临床意义。
Br Med J. 1978 Sep 2;2(6138):655-7. doi: 10.1136/bmj.2.6138.655.
2
Polymorphic hydroxylation of Debrisoquine in man.人对异喹胍的多态性羟基化作用。
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.
Zotero 插件